TEMOVATE Drug Patent Profile

Which patents cover Temovate, and when can generic versions of Temovate launch?

Temovate is a drug marketed by Fougera Pharms and is included in five NDAs.

The generic ingredient in TEMOVATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Temovate

A generic version of TEMOVATE was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Summary for TEMOVATE

US Patents:	0
Applicants:	1
NDAs:	5

US Patents and Regulatory Information for TEMOVATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fougera Pharms	TEMOVATE	clobetasol propionate	CREAM;TOPICAL	019322-001	Dec 27, 1985		DISCN	Yes	No
Fougera Pharms	TEMOVATE	clobetasol propionate	SOLUTION;TOPICAL	019966-001	Feb 22, 1990		DISCN	Yes	No
Fougera Pharms	TEMOVATE	clobetasol propionate	GEL;TOPICAL	020337-001	Apr 29, 1994		DISCN	Yes	No
Fougera Pharms	TEMOVATE	clobetasol propionate	OINTMENT;TOPICAL	019323-001	Dec 27, 1985		DISCN	Yes	No

International Patents for TEMOVATE

See the table below for patents covering TEMOVATE around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	350035
United Kingdom	1253831
Switzerland	564035
Netherlands	6900795

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for TEMOVATE

Last updated: February 3, 2026

Executive Summary

TEMOVATE (generic: clobetasol propionate) is a potent topical corticosteroid used primarily to treat inflammatory skin conditions such as eczema, psoriasis, and dermatitis. This report evaluates the investment landscape, industry drivers, regulatory environment, and financial outlook for TEMOVATE—considering market size, competitive positioning, patent status, and growth prospects. The analysis underscores an increased demand driven by dermatology therapeutics, exemplified by high prescription volumes, but also notes potential challenges related to generic competition, regulatory shifts, and safety concerns.

Market Overview and Size

Parameter	Details	Source/Notes
Global dermatology drug market (2022)	Approx. USD 21.4 billion	[1]
Topical corticosteroids market share	~25% of dermatology drugs	[2]
Estimated annual sales of TEMOVATE	USD 200–400 million (2022)	Based on prescription data and market share estimates
Major market regions	US, Europe, APAC	[3]

Drug Profile & Usage

• Active Ingredient: Clobetasol propionate
• Formulation: Topical cream, ointment, foam
• Indications: Psoriasis, eczema, dermatitis, other inflammatory skin conditions
• Administration: Twice daily application

Market Dynamics

Demand Drivers

• Rising Prevalence of Skin Disorders: Global increase attributed to lifestyle, environmental factors, and aging populations.
• Physician Prescribing Trends: Preference for potent corticosteroids like TEMOVATE for short-term management of severe conditions.
• Patient Compliance: Availability in multiple formulations enhances adherence.

Competitive Landscape

Competitors	Key Products	Market Share	Notes
Teva	Clobetasol formulations	Significant	Generic dominant in many markets
Mylan	Similar off-patent drugs	Significant	Price competition
Perrigo	OTC versions	Niche	Focus on OTC availability
Branded alternatives	Encompet, Diprolate	Limited	Usually prescriber preference-driven

Regulatory and Patent Landscape

• Patent Status: Clobetasol propionate patents expired in early 2010s, leading to high generic penetration.
• Regulatory Environment: Post-patent expiry, focus shifts to market access, bioequivalence, and compliance. Stringent regulations in the US (FDA) and EU (EMA) impact launch strategies.
• Safety Concerns & Restrictions: Potential for side effects like skin atrophy necessitates restriction in long-term use, influencing prescribing behaviors.

Market Entry and Distribution Channels

• Distribution: Dermatology clinics, pharmacies, hospitals.
• Pricing & Reimbursement: Varies by country; government-managed reimbursements in Europe and US Medicaid influence sales.

Financial Trajectory and Forecast

Parameter	2022 Actual	2023–2027 Projection	Notes
Revenue	USD 200–400M	USD 250–450M	Moderate growth due to generics’ competitive pressure
Market CAGR	~3–4%	3%	Driven by steady dermatological needs
Gross Margin	~60%	55–60%	Price erosion from competition
R&D Investment	Varies	Low for generics, higher for biosimilars	Shifted towards innovation in new formulations

Profitability Analysis

• Generic Saturation: Intense price competition is compressing margins.
• Cost Structures: Manufacturing costs are relatively stable; marketing expenses focus on distribution and physician outreach.
• Regulatory Adjustments: Reimbursement and approval hurdles can impact revenue generation.

Investment Outlook

• Short-to-Medium Term (1–3 years): Steady cash flow with moderate growth prospects.
• Long-term (3+ years): Potential revenue plateau unless innovation or new indications emerge.

Comparison: TEMOVATE vs. Similar Drugs

Aspect	TEMOVATE (Clobetasol propionate)	Encompet (Budesonide)	Diprolene (Betamethasone dipropionate)
Potency	Super-high	Medium-high	High
Patent Status	Expired	Expired	Expired
Market Share	Leading in super-high potency	Niche	Niche
Safety Profile	Requires cautious use	Similar	Similar

Regulatory Environment & Impact on Financials

Region	Regulatory Body	Key Regulations	Impact on TEMOVATE
US	FDA	OTC and prescription guidelines, REMS	Tight restrictions due to side effects
EU	EMA	Ccknowledgement of risk-benefit ratio	Access thresholds
Asia-Pacific	Varies	Less stringency, high growth	Market expansion opportunities

Growth Opportunities & Risks

Opportunities

• Expansion into emerging markets with unmet dermatological needs.
• Development of lower-potency formulations for long-term safety.
• Strategic formulations developments to enhance patient adherence.

Risks

• Price erosion from generic competition.
• Increasing safety concerns leading to prescribing restrictions.
• Regulatory hurdles delaying market access.
• Emergence of biosimilars or alternative therapies.

Conclusion

TEMOVATE's investment outlook remains cautiously optimistic. Market demand persists amid intense generic competition, but profitability margins are under pressure. Strategic positioning through formulation innovation, geographic expansion, and compliance with evolving regulations could sustain or enhance its financial trajectory.

---

Key Takeaways

• Market stability driven by consistent dermatological need supports moderate growth, despite patent expirations.
• Generic competition significantly impacts pricing and margins; manufacturers must innovate or diversify.
• Regulatory landscapes influence timing and scope of market expansion, especially in emerging regions.
• Safety concerns lead to prescriber caution, affecting long-term sales potential.
• Growth prospects hinge on geographic diversification, formulation enhancements, and potential new indications.

---

FAQs

1. How does patent expiration affect TEMOVATE's market position?
Patent expiration in early 2010s led to increased generic entries, intensifying price competition and reducing brand premium.

2. What are the key safety concerns impacting TEMOVATE's prescription?
Potential side effects such as skin atrophy and systemic absorption restrict long-term use, influencing prescribing patterns.

3. Which regions offer the highest growth potential for TEMOVATE?
Emerging markets in Asia-Pacific and Latin America offer expanding dermatological needs and less saturated markets.

4. How does the competitive landscape influence pricing?
High generic competition drives prices downward, compressing profit margins but maintaining volume sales.

5. What strategic actions can manufacturers pursue to sustain profitability?
Innovations in formulation, exploring new indications, expanding into OTC markets, and geographic diversification are key strategies.

---

References

[1] MarketResearch.com, "Global Dermatology Drugs Market," 2022.
[2] IMS Health, "Topical Corticosteroids Market Share," 2021.
[3] EvaluatePharma, "Pharmaceutical Market Trends," 2022.